Study of the Practice of Debiri in France
- Sponsor
- Federation Francophone de Cancerologie Digestive
- Study ID
- NCT03369041
- Status
- Unknown
Conditions
- Colorectal Adenocarcinoma
- Hepatic Metastases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 130 Years
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan-Eluting Beads — DRUG
Study Details
In order to extract the profiles of patients receiving DEBIRI treatment at best, the investigators proposed the establishment of a national prospective cohort to collect information on the greatest number of patients treated with DEBIRI. This cohort will allow a better understanding of the effectiveness, tolerance, feasibility and differences of practices at national level for this approach. These data will assist in the development of clinical trials in situations that appear to be most promising in clinical practice.
Key Dates
- Start date
- Feb 3, 2016
- Status verified
- Aug 2022
- Primary completion
- Oct 15, 2022
- Completion
- Oct 15, 2022
Study Design
- Enrollment
- 70 participants (actual)
Primary Outcome Measure
Progression free survival (PFS) and/or hepatic progression free survival [ Time Frame: 3 years after inclusion ]
Related Studies
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasPHASE1 · Recruiting · Inhibrx Biosciences, Inc · Scottsdale, Arizona
- Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C StudyRecruiting · M.D. Anderson Cancer Center · Gilbert, Arizona
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionPHASE1/PHASE2 · Recruiting · A2 Biotherapeutics Inc. · Gilbert, Arizona
- Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal CancerPHASE1 · Recruiting · Jonsson Comprehensive Cancer Center · Los Angeles, California